MA26.02 Upfront or Sequential Strategy for New Generation Anaplastic Lymphoma Kinase (ALK) Inhibitors: An Italian Retrospective Study.
Élisa Gobbini(Institut Curie), Silvia Novello(University of Turin), Massimo Di Maïo(University of Siena), Claudia Bareggi(University of Milan), Olga Martelli(Agostino Gemelli University Polyclinic), Vieri Scotti(University of Florence), Paola Bordi, Sara Pilotto(University of Verona), Rita Chiari(Azienda Ospedaliera di Perugia), Gloria Borra, Emilio Bria(Università Cattolica del Sacro Cuore), Antônio Rossi(Università Campus Bio-Medico), Paolo Graziano(Pathological Society), Vanesa Gregorc(IRCCS Ospedale San Raffaele), Fabiana Letizia Cecere, Evaristo Maiello(Casa Sollievo della Sofferenza), Pamela Pizzutilo(Istituto Tumori Bari), Giulio Rossi(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Diego Cortinovis(Azienda Ospedaliera San Gerardo), Laura Ghilardi(Ospedale Papa Giovanni XXIII), Angelo Delmonte(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Clelia Casartelli(Ospedale Valduce), P. Rizzo(Institute for Coastal Marine Environment), Claudio Dazzi(Azienda Ospedaliero-Universitaria Careggi), Alessandro Del Conte(University of Catania), Concetta Sergi(Ospedale Garibaldi), Giorgia Osman, Ferdinando Riccardi(Ospedale Antonio Cardarelli)
Cited by 1
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k
Non-small-cell lung cancer
|Nature Reviews Disease Primers|2015|1.1k
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2023|1k